We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-22.24%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$45.1M
AUM Growth
-$24.4M
(-35%)
Cap. Flow
-$1.22M
Cap. Flow
% of AUM
-2.7%
Top 10 Holdings %
Top 10 Hldgs %
94.6%
Holding
45
New
12
Increased
6
Reduced
10
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
China SXT Pharmaceuticals
SXTC
|
+$2.01M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.63M |
| 3 |
ALP
Alpha Compute
ALP
|
+$1.15M |
| 4 |
BCTXL
BriaCell Therapeutics Warrant
BCTXL
|
+$403K |
| 5 |
BCTX
Briacell Therapeutics
BCTX
|
+$344K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EMPD
Empery Digital
EMPD
|
+$1.56M |
| 2 |
Blink Charging
BLNK
|
+$1.42M |
| 3 |
BTM
Bitcoin Depot
BTM
|
+$1.29M |
| 4 |
ABVX
Abivax
ABVX
|
+$831K |
| 5 |
DSY
Big Tree Cloud Holdings
DSY
|
+$637K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 92.21% |
| 2 | Healthcare | 3.11% |
| 3 | Financials | 1.47% |
| 4 | Materials | 1.13% |
| 5 | Consumer Staples | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
| $29.1M | 64.5% |
447
+98
| +28% | +$66.6K |
|
2
PUT
iShares S&P 100 ETF
OEF
$20.5B
| $7.44M | 16.51% |
300
-350
| -54% | -$117K |
|
|
3
State Street SPDR S&P 500 ETF Trust
SPY
$827B
| $1.78M | 3.94% |
2,734
+2,399
| +716% | +$1.63M |
|
4
PUT
Gevo
GEVO
$415M
| $1.43M | 3.18% |
5,252
-1,022
| -16% | -$2.12K |
|
|
ABVX
5
CALL
Abivax
ABVX
$9.97B
| $857K | 1.9% |
77
-83
| -52% | -$9.82K |
|
|
ALP
6
Alpha Compute
ALP
$4.14M
| $655K | 1.45% |
+2,072,103
| New | +$1.15M |
|
|
BCTXL
7
BriaCell Therapeutics Warrant
BCTXL
$2.6M
| $392K | 0.87% |
+380,686
| New | +$403K |
|
8
SenesTech
SNES
$5.97M
| $358K | 0.8% |
218,533
+7,969
| +4% | +$16.1K |
|
|
DSY
9
Big Tree Cloud Holdings
DSY
$18.7M
| $337K | 0.75% |
137,611
-150,888
| -52% | -$637K |
|
10
PUT
Zevra Therapeutics
ZVRA
$704M
| $317K | 0.7% |
340
+13
| +4% | +$117 |
|
|
BCTX
11
Briacell Therapeutics
BCTX
$32.3M
| $310K | 0.69% |
+73,915
| New | +$344K |
|
12
PUT
Sidus Space
SIDU
$236M
| $243K | 0.54% |
+1,049
| New | +$2.86K |
|
|
TC
13
TuanChe
TC
$51M
| $242K | 0.54% |
+23,239
| New | +$247K |
|
14
Pop Culture Group
CPOP
$4.38M
| $201K | 0.45% |
66,445
-29,219
| -31% | -$108K |
|
15
Moleculin Biotech
MBRX
$13.4M
| $172K | 0.38% |
+75,021
| New | +$248K |
|
|
BDRX
16
Biodexa Pharmaceuticals
BDRX
$926K
| $159K | 0.35% |
51,494
+13,362
| +35% | +$94K |
|
17
Arcadia Biosciences
RKDA
$1.24M
| $158K | 0.35% |
+114,554
| New | +$224K |
|
18
TRX Gold Corp
TRX
$400M
| $150K | 0.33% |
+100,000
| New | +$148K |
|
19
InMed Pharmaceuticals
INM
$7.64M
| $142K | 0.32% |
220,260
+18,627
| +9% | +$17.6K |
|
|
CANF
20
Can-Fite BioPharma American Depositary Shares
CANF
$7.22M
| $132K | 0.29% |
+42,559
| New | +$176K |
|
|
21
China SXT Pharmaceuticals
SXTC
$1.85M
| $131K | 0.29% |
+977
| New | +$2.01M |
|
22
Revelation Biosciences
REVB
$4.1M
| $119K | 0.26% |
99,432
-51,994
| -34% | -$101K |
|
23
Calidi Biotherapeutics
CLDI
$3.36M
| $104K | 0.23% |
+27,181
| New | +$327K |
|
24
Bluejay Diagnostics
BJDX
$941K
| $52.9K | 0.12% |
+28,726
| New | +$71K |
|
|
LYRA
25
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $51.1K | 0.11% |
104,059
-71,099
| -41% | -$130K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q1 2026 Portfolio in Review
As of Q1 2026, Sabby Management held 45 positions worth $45.1M, down 35% from $69.5M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Sabby Management's Q1 2026 filing shows 12 new, 6 increased, 10 reduced and 17 closed positions. Its largest new stake was China SXT Pharmaceuticals: 977 shares worth $131K. The largest sale was Empery Digital, an estimated $1.56M.
By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 83% a quarter earlier, followed by Healthcare and Financials.
- Sabby Management's largest Q1 2026 buy was China SXT Pharmaceuticals: 977 shares worth $131K.
- Sabby Management added most to State Street SPDR S&P 500 ETF Trust in Q1 2026, an estimated $1.63M increase.
- Sabby Management's biggest Q1 2026 reduction was Big Tree Cloud Holdings, cutting an estimated $637K.
- Sabby Management fully exited Empery Digital in Q1 2026, selling an estimated $1.56M.
- Sabby Management's ten largest holdings make up 95% of its $45.1M portfolio in Q1 2026.
- Sabby Management opened 12 new positions and closed 17 in Q1 2026.
- Sabby Management's portfolio value fell 35% quarter-over-quarter to $45.1M.
Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.